Multiple Myeloma: The Blood Cancer That Attacks Bones and Kidneys
When 62-year-old David visited his doctor complaining of persistent back pain, he assumed he’d pulled a muscle. X-rays revealed a shocking truth: his spine was riddled with holes, and blood tests showed abnormal proteins flooding his system. Diagnosis: multiple myeloma—a blood cancer that silently destroys bones from the inside while overwhelming kidneys with toxic proteins. As myeloma cells multiply in the bone marrow, they crowd out normal cells, meaning decreased numbers of red blood cells, white blood cells, and platelets. The buildup of abnormal protein in the blood and urine can damage the kidneys and other organs. Myeloma cells may activate other cells that damage your bones, causing bone pain and weakened spots called osteolytic lesions. This bone destruction increases fracture risk and leads to increased blood calcium levels MMRF. Understanding how this cancer simultaneously attacks multiple organ systems reveals why myeloma proves so devastating and why treatment requires attacking the disease from several angles.
What Multiple Myeloma Is
Multiple myeloma accounts for approximately 10% of hematologic malignancies. Each year over 35,000 new cases are diagnosed in the United States, and almost 13,000 patients die of the disease. The annual age-adjusted incidence in the United States has remained stable for decades at approximately 4 per 100,000. Multiple myeloma is slightly more common in men than women, and is twice as common in African-Americans compared with Caucasians. The median age of patients at diagnosis is about 65 years PubMed Central. Multiple myeloma starts in plasma cells—a type of white blood cell normally producing antibodies to fight infections. In myeloma, these cells become cancerous and multiply uncontrollably in bone marrow. Instead of producing helpful antibodies, they churn out abnormal proteins called M-proteins or paraproteins that serve no useful purpose but cause enormous damage. These malignant plasma cells crowd bone marrow, leaving no room for normal blood cell production. The abnormal proteins they secrete clog kidneys, damage nerves, thicken blood, and trigger excessive bone breakdown. Unlike leukemias where cancer cells circulate in blood, myeloma cells stay mostly in bone marrow—but their effects reach everywhere.
The CRAB Criteria: How Myeloma Reveals Itself
The diagnosis of multiple myeloma requires the presence of one or more myeloma defining events (MDE) in addition to evidence of either 10% or more clonal plasma cells on bone marrow examination. MDE consists of established CRAB features: hypercalcemia, renal failure, anemia, or lytic bone lesions WikipediaWiley Online Library. Doctors use the acronym CRAB to remember myeloma’s four major manifestations. Each letter represents a different way the cancer damages the body, and patients often have multiple CRAB features simultaneously. C is for hypercalcemia—elevated blood calcium from excessive bone breakdown. Symptoms include confusion, excessive thirst, frequent urination, constipation, nausea, and kidney stones. Severe cases cause cardiac arrhythmias and coma. R is for renal insufficiency—kidney damage from protein overload. A is for anemia—low red blood cells causing fatigue, weakness, shortness of breath, and dizziness as myeloma crowds out normal blood cell production. B is for bone lesions—punched-out holes weakening bones throughout the skeleton, causing pain, fractures from minimal trauma, and spinal cord compression when vertebrae collapse.
Why Myeloma Destroys Bones
Multiple myeloma leads to bone loss in two ways. First, multiple myeloma cells form masses in the bone marrow that disrupt normal bone structure. Second, myeloma cells boost activity of other cells responsible for breaking down bone. This causes small holes called lytic lesions to develop in bones, which weakens them MMRF. Normal bones constantly remodel through balanced activity of osteoblasts (cells building new bone) and osteoclasts (cells breaking down old bone). Myeloma cells produce factors that massively stimulate osteoclasts while inhibiting osteoblasts. This creates pure bone destruction without replacement—leaving punched-out holes visible on X-rays. Unlike other malignancies that metastasize to bone, the osteolytic bone lesions in multiple myeloma exhibit no new bone formation. Bone disease is the main cause of morbidity and can be best detected using low-dose whole body computed tomography, PET/CT scans, or magnetic resonance imaging PubMed Central. These lytic lesions most commonly affect spine, skull, ribs, pelvis, and long bones. On skull X-rays, they create a characteristic “raindrop” or “Swiss cheese” appearance. Bones become so fragile that patients suffer fractures from routine activities like coughing, bending, or turning over in bed. Vertebral compression fractures cause severe back pain and height loss as spine collapses. The calcium released from dissolving bone floods the bloodstream, causing hypercalcemia that further damages kidneys and creates a vicious cycle.
The Kidney Catastrophe
Kidney failure is a common complication of multiple myeloma. When first diagnosed, as many as 20-40% of patients with multiple myeloma will have some kidney failure. The abnormal proteins made by plasma cells float around in the bloodstream. Blood passes through kidney filters and these abnormal proteins enter the tubules. These proteins can join with another protein normally present in urine, Tamm Horsfall protein. If these two proteins join together they become too big to pass through the tubules and cannot exit the kidney in the form of urine. This combination results in large casts that block the tubules inside the kidney UNC Kidney CenterNCBI. Think of kidney tubules as thousands of tiny pipes carrying filtered blood toward becoming urine. Abnormal light chains—small protein fragments produced by myeloma cells—pass through glomeruli (kidney filters) because they’re small enough. But in the tubules, they bind with Tamm-Horsfall protein forming enormous protein complexes called casts that plug the pipes like hair clogging a drain. With tubules blocked, kidneys can’t filter waste, leading to acute kidney injury. Cast nephropathy is by far the most common renal disease associated with multiple myeloma, found in 40% to 60% of renal biopsies in patients with multiple myeloma and kidney disease. Light chain cast nephropathy typically reveals the underlying myeloma and manifests with severe acute kidney injury, high serum free light chain level (>500 mg/L) and predominant light chain proteinuria ScienceDirect. Additional kidney damage mechanisms include: light chain deposition disease where proteins deposit in kidney tissue causing scarring; amyloidosis where proteins form insoluble fibrils clogging kidney structures; hypercalcemia from bone breakdown reducing kidney blood flow; dehydration from calcium-induced excessive urination; and infections affecting immunocompromised patients. The prognosis for multiple myeloma depends in large part on if the kidney is affected and how badly. Patients who have kidney dysfunction will have average survival of 20 months. Those without kidney dysfunction will have average survival of 40 months. Among all patients, response to chemotherapy is important—patients whose kidney function improves with chemotherapy have average survival of 3 years UNC Kidney Center.
Diagnosis And Modern Treatment
Diagnosis requires bone marrow biopsy showing abnormal plasma cells, blood/urine tests detecting M-protein, and imaging revealing bone lesions. Treatment has transformed dramatically with targeted therapies and immunotherapy. Modern regimens combine proteasome inhibitors (bortezomib, carfilzomib), immunomodulatory drugs (lenalidomide, pomalidomide), monoclonal antibodies (daratumumab, elotuzumab), and steroids. For younger patients, high-dose chemotherapy followed by autologous stem cell transplantation can extend remission. CAR-T cell therapy—genetically engineering patient’s T-cells to attack myeloma—shows remarkable promise, with FDA approval expanding in 2024. Bispecific antibodies simultaneously bind myeloma cells and T-cells, bringing immune cells directly to cancer. Supportive care includes bisphosphonates preventing bone loss, radiation for painful lesions, and aggressive hydration protecting kidneys. With modern therapy, median survival exceeds 8-10 years for many patients—dramatically improved from 3-4 years two decades ago.
Frequently Asked Questions
Q1: What causes the bone pain in multiple myeloma?
Bone pain results from three mechanisms: lytic lesions weakening bones create microfractures causing pain even without complete breaks; myeloma cells expanding in marrow create pressure stretching the bone’s outer membrane (periosteum) which has abundant pain nerves; and pathologic fractures from severely weakened bone breaking under normal stress. Pain typically affects back, ribs, and hips—areas with abundant marrow. It’s often worse at night and with movement. Unlike arthritis pain that improves with activity, myeloma bone pain worsens with use. Some patients develop sudden severe pain from vertebral compression fractures—spine collapsing under body weight. Treatment includes radiation to painful lesions, bisphosphonates reducing bone breakdown, pain medications, and chemotherapy reducing myeloma burden.
Q2: Can kidney damage from myeloma be reversed?
Sometimes—if caught early and treated aggressively. When light chains plug kidney tubules, immediate action can restore function: aggressive IV hydration flushes tubules; emergency chemotherapy rapidly reduces myeloma cells producing toxic proteins; plasmapheresis mechanically removes light chains from blood; and avoiding nephrotoxic drugs prevents additional damage. Studies show 20-60% of patients with myeloma kidney injury recover significant kidney function with prompt treatment. However, delayed diagnosis allowing prolonged obstruction and scarring makes recovery unlikely. Some patients require temporary or permanent dialysis. The key: recognizing kidney injury early through monitoring, starting treatment immediately, and achieving rapid reduction in light chain levels.
Q3: Why do myeloma patients get so many infections?
Multiple factors compromise immunity: myeloma cells crowd bone marrow preventing normal white blood cell production; malignant plasma cells produce useless abnormal antibodies instead of protective ones fighting infections; chemotherapy further suppresses immune function; and steroids (common treatment) broadly inhibit immunity. Common infections include pneumonia, urinary tract infections, and shingles. Some patients receive monthly intravenous immunoglobulin (IVIG) infusions replacing missing antibodies. Vaccinations are recommended before starting therapy when immune response is better. Prophylactic antibiotics prevent certain infections. Any fever requires urgent evaluation—infections can progress rapidly in immunocompromised patients and prove fatal if untreated.
Q4: Is myeloma hereditary? Should my children be tested?
Myeloma itself isn’t directly inherited, but genetic susceptibility exists. First-degree relatives (parents, siblings, children) have 2-4 times higher risk than general population—still very low absolute risk. Most cases arise sporadically without family history. African-Americans face double the risk for unclear reasons possibly involving genetic variants. Currently, no screening tests are recommended for asymptomatic relatives. However, relatives should be aware of symptoms—unexplained bone pain, fatigue, frequent infections, kidney problems—and report them promptly. Some families with multiple affected members participate in research studying hereditary factors. Unless multiple close relatives have myeloma, routine screening isn’t warranted.
Q5: What’s the difference between smoldering myeloma and active myeloma?
Smoldering (asymptomatic) myeloma has abnormal plasma cells and M-protein but no CRAB features—no symptoms or organ damage. It’s a precursor state requiring monitoring, not treatment. About 10% per year progress to active disease requiring intervention. Active (symptomatic) myeloma has one or more CRAB features or specific high-risk markers indicating imminent organ damage. Treatment starts immediately for active disease but is usually deferred for smoldering disease unless high-risk features exist. Recent studies test whether treating high-risk smoldering disease early prevents progression, but this remains controversial. Most patients with smoldering myeloma undergo regular monitoring—every 3-6 months—watching for progression signs rather than starting treatment prematurely.
Disclaimer
This article adapts publicly available information from reputable hematology research organizations and medical databases. This content is for informational and educational purposes only and does not constitute medical advice. ObserverVoice.com is a news and information platform — not a healthcare provider. Decisions about multiple myeloma diagnosis and treatment should be made in consultation with qualified hematologists and oncologists who can evaluate your individual disease characteristics, bone and kidney involvement, and overall health. If you have been diagnosed with myeloma, please consult with your healthcare team promptly to discuss appropriate treatment options.
References
- Multiple Myeloma Research Foundation. What is Multiple Myeloma? https://themmrf.org/multiple-myeloma/
- PMC. Multiple Myeloma: 2024 update on Diagnosis, Risk-stratification and Management. https://pmc.ncbi.nlm.nih.gov/articles/PMC11404783/
- UNC Kidney Center. Myeloma Kidney. https://unckidneycenter.org/kidneyhealthlibrary/glomerular-disease/myeloma-kidney/
- StatPearls. Renal Disease in Monoclonal Gammopathies. https://www.ncbi.nlm.nih.gov/books/NBK499952/
- Merck Manual. Myeloma-Related Kidney Disease. https://www.merckmanuals.com/professional/genitourinary-disorders/tubulointerstitial-diseases/myeloma-related-kidney-disease
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
